Moleculin Reports Full Year 2025 Financial Results and Pivotal MIRACLE Trial Update

Moleculin Biotech reported full-year 2025 financial results and confirmed that the highly anticipated 45-patient interim data unblinding in its pivotal MIRACLE trial is on track for mid-2026. The trial's preliminary blinded CRc rate of 40% in the first 30 patients suggests encouraging early results in relapsed/refractory AML. The company is also progressing with a new Annamycin research collaboration for glioblastoma multiforme and a Phase 1 clinical trial of WP1066 in pediatric recurrent malignant brain tumors.